Devonian Reports Results of its Annual General and Special Meeting of Shareholders

Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical ...
Business Wire

Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to ...

Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026

Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical ...
Stockhouse

Devonian Appoints André P. Boulet to Chairman of the Board and Chief Operating Officer

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on ...
USA Today

From Seed to Pill: How Devonian Health Group Brings Botanicals to Market

As more people look for natural health treatments, they look at the true journey of the products they plan to apply to their skin. Right from how sustainable the company is to where the ingredients ...
Business Wire

Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory ...